Displaying drugs 11476 - 11500 of 11571 in total
NBI-6024
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigational
Banoxantrone
Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. Banoxantrone was also efficacious in...
Investigational
Matched Description: … Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic …
Seliciclib
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex...
Investigational
Matched Description: … R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration …
MBO7133
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP. However, araC is only slowly...
Investigational
Matched Description: … MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is ... MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver. …
Darapladib
Investigational
PF-07304814
PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects . PF-07304814, developed by Pfizer, was first identified during the...
Investigational
Matched Description: … PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) …
Hesperetin
Hesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside hesperidin, is the predominant flavonoid in lemons and oranges.
Experimental
Iclaprim
Investigational
CoVac-1
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein . It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults...
Investigational
Matched Description: … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine …
Olmutinib
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
Osanetant
Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant....
Investigational
Matched Description: … In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further …
Grn163l
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the...
Investigational
Matched Description: … GRN163L is a novel anti-cancer drug. …
Regramostim
Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of...
Investigational
Matched Description: … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and …
ROX-888
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
Tucidinostat
Investigational
Namilumab
Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
Investigational
3-Methylfentanyl
3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000 times more potent than morphine in certain cases. 3-Methylfentanyl was initially discovered in 1974 and widespread illegal use...
Illicit
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
Umbilical Cord Blood Hematopoietic Stem Cells
The use of umbilical cord blood (UCB) for therapies is advantageous because of its ease of access, non-invasive collection procedures, and more plasticity for multi-differentiation. UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to...
Investigational
Matched Description: … UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have …
LX1031
LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. LX1031 is designed to act locally in the gastrointestinal tract by...
Investigational
Matched Description: … LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key …
Telcagepant
Telcagepant has been investigated for the treatment of Migraine. It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the...
Investigational
Matched Description: … It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide …
Famprofazone
Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin’ which is marketed in Taiwan. It is important to note that the drug is metabolized to methamphetamine and amphetamine in the body and can lead to positive tests results for illicit drug use.[A236369,L34724] Famprofazone is included in...
Experimental
Matched Description: … Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin …
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Displaying drugs 11476 - 11500 of 11571 in total